-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis (SWX:NOVN) Faces A 7% Fair Value Gap After Cosentyx CHMP Backing

Simply Wall St·11/16/2026 20:19:39
Listen to the news

Novartis (SWX:NOVN) is back in focus after regulators in Europe issued a positive CHMP opinion for Cosentyx in adolescents with moderate to severe hidradenitis suppurativa, a step that could expand its immunology reach.

These Cosentyx and Rhapsido updates arrive with Novartis shares trading at CHF135.76 and clear positive momentum building, with a 30-day share price return of 8.9% and year-to-date gain of 25.1%, while the 5-year total shareholder return of 126.2% reflects longer term compounding.

Scan beyond Novartis and line up other potential immunology and healthcare beneficiaries with the curated 125 healthcare AI stocks that could participate in similar adoption and treatment trends.

After a strong run into CHF135.76, Novartis still screens at a sizeable intrinsic discount, even though the share price sits above the average analyst target. Is the market being overly cautious, or appropriately sceptical about that gap?

Most Popular Narrative: 7% Overvalued

On the analyst consensus Narrative on Simply Wall St, Novartis screens as modestly expensive, with a fair value of CHF126.97 against the latest CHF135.76 close, and the gap tied directly to how dependable its growth engines look.

The main requirement is continued execution on high-growth platforms such as radioligand therapies, remibrutinib and cardiovascular assets, while maintaining high core margins despite ongoing loss-of-exclusivity and Xolair profit share erosion.

The current valuation implies that Novartis is fairly valued, with the market already pricing in the replacement of major loss-of-exclusivity products, delivery on platform assets like remibrutinib and radioligand therapies, and sustained high core operating margins.

See why 119 investors see Novartis as 7% overvalued.

Result: Fair Value of CHF126.97 (OVERVALUED)

Still, the Novartis story can change quickly if loss of exclusivity hits harder than expected or if more late stage trials fail to deliver.

Find out about the key risks to this Novartis narrative.

Another View: Novartis Through The P/E Lens

A different angle on Novartis comes from its current P/E of 30.4x. That is richer than the European pharmaceuticals average of 20.1x, yet it sits below a fair ratio of 56.1x and a peer average of 48.3x. This combination points to higher pricing risk but also room for re-rating if sentiment shifts.

For a closer look at how this valuation stacks up in practice, including how that fair ratio might act as a reference point for future pricing moves, See what the numbers say about this price — find out in our valuation breakdown.

SWX:NOVN P/E Ratio as at Nov 2026
SWX:NOVN P/E Ratio as at Nov 2026

Next Steps

Mixed messages in the Novartis story today. If you want to move fast and still think clearly, consider both sides by checking the 3 key rewards and 3 important warning signs.

Looking for more ideas beyond Novartis?

If Novartis has your attention, broaden your opportunity set with a few curated stock lists that target different strengths so you do not miss what fits you best.